Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-06053-y
Abstract: Purpose HER2-targeted therapies are associated with cardiotoxicity which is usually asymptomatic and reversible. We report the updated cardiac safety assessment of patients with compromised heart function receiving HER2-targeted therapy for breast cancer, enrolled in the… read more here.
Keywords: heart; targeted therapies; her2 targeted; breast cancer ... See more keywords
Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-024-01399-3
Abstract: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer presents considerable treatment challenges owing to its aggressive nature. Global guidelines have endorsed a full year of HER2-targeted therapy for early-stage breast cancer. However, previous cost-effectiveness… read more here.
Keywords: breast cancer; her2; cost; her2 targeted ... See more keywords
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0235-2
Abstract: BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m2 every 4… read more here.
Keywords: phase; dose escalation; her2 targeted; cancer ... See more keywords
Targeting fatty acid oxidation enhances response to HER2-targeted therapy
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-50998-3
Abstract: Metabolic reprogramming, a hallmark of tumorigenesis, involves alterations in glucose and fatty acid metabolism. Here, we investigate the role of Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme in long-chain fatty acid (LCFA) oxidation, in… read more here.
Keywords: targeting fatty; acid oxidation; her2; her2 targeted ... See more keywords
HER2-targeted therapies — a role beyond breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0268-3
Abstract: HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of… read more here.
Keywords: breast cancer; her2 targeted; cancer; her2 ... See more keywords
Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-14064-2
Abstract: Human epidermal growth factor receptor 2 (HER2)-targeted therapies, including monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs), have significantly improved clinical outcomes in HER2-positive cancers. However, hepatotoxicity remains a major concern… read more here.
Keywords: ror; analysis; her2 targeted; targeted drugs ... See more keywords
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1520838
Abstract: ABSTRACT Introduction: One-third of breast cancer (BC) cases worldwide occur in women aged 65 years and older, with 10 to 15% overexpressing the human epidermal growth factor receptor 2 (HER2). Although several HER2-targeted therapies have… read more here.
Keywords: older adults; targeted therapies; her2 targeted; breast cancer ... See more keywords
Experimental HER2- targeted therapies for biliary tract cancer
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2021.1854724
Abstract: ABSTRACT Introduction: Biliary tract cancers (BTCs) constitute a heterogeneous group of poor-prognosis solid tumors with limited treatment options. In the last decade, global efforts have tried to identify therapeutic targets by genomic profiling of BTC,… read more here.
Keywords: biliary tract; her2 targeted; cancer; her2 ... See more keywords
Companion diagnostics and HER2-targeted antibody-drug conjugates.
Sign Up to like & getrecommendations! Published in 2025 at "Expert review of molecular diagnostics"
DOI: 10.1080/14737159.2025.2587617
Abstract: ABSTRACT Introduction HER2-targeted antibody-drug conjugates (ADCs) have shown promising outcomes in the treatment of patients with various HER2-expressing solid tumors. The efficacy of ADCs is influenced by several factors, such as the antibody properties, linker… read more here.
Keywords: drug; antibody drug; her2 targeted; drug conjugates ... See more keywords
Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1394454
Abstract: ABSTRACT Background: Using network meta-analysis, we assessed the efficacy and safety of a combination regimen of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer. Methods: We searched the Medline, Embase, and Cochrane Library… read more here.
Keywords: network meta; first line; line treatment; her2 targeted ... See more keywords
Cardiotoxicity of HER2-targeted therapies.
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Cardiology"
DOI: 10.1097/hco.0000000000000637
Abstract: PURPOSE OF REVIEW Cardiotoxicity is a well recognized adverse effect of human epidermal growth factor receptor 2 (HER2)-targeted therapies. The goal of this review is to highlight recent studies that have advanced our knowledge of… read more here.
Keywords: risk; her2 targeted; targeted therapies; cardiotoxicity her2 ... See more keywords